🇺🇸 FDA
Patent

US 6320074

Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors

expired A61PA61P17/00A61P3/02

Quick answer

US patent 6320074 (Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors) held by Ligand Pharmaceuticals Incorporated expires Mon Nov 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue Nov 20 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
41
CPC classes
A61P, A61P17/00, A61P3/02, A61P3/06, A61P35/00